Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
2
×
boston blog main
boston top stories
deals
life sciences
national blog main
san francisco blog main
abbvie
allergan
alzheimer's disease
azacitidine
beta-thalassemia
clinical trials
crispr
cynthia collins
dacogen
decitabine
dna
editas medicine
epigenetics
epizyme
farydak
flagship pioneering
fulcrum therapeutics
gene editing
insulated genomic domains
kaleido biosciences
leber congenital amaurosis type 10
mahesh karande
michelle robertson
national top stories
new york blog main
new york top stories
omega therapeutics
panobinostat
parkinson's disease
rare diseases
richard young
robert gould
What
biotech
2
×
medicines
research
2
×
abbvie
aims
alliance
approach
based
called
debuts
developing
drugs
editas
editing
epigenetic
epigenetics
exits
experimental
field
flagship’s
gene
genetic
morning
new
omega
pact
partnership
pruning
returning
rights
startup
step
terminated
therapeutics
touting
treatment
Language
unset
Current search:
biotech
×
boston
×
research
×
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further